Stockscreener 앱 받기
9.16
2.24%
-0.21
시간 외 거래:
9.16
Astria Therapeutics Inc 주식(ATXS)의 최신 뉴스
Research Analysts Set Expectations for ATXS FY2024 Earnings - MarketBeat
Astria Therapeutics’ (ATXS) Buy Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 - Defense World
Astria Therapeutics Reports Q3 2024 Financial Results - MSN
Astria Therapeutics (NASDAQ:ATXS) Shares Down 5.3%Time to Sell? - MarketBeat
RA Capital Management, L.P. Expands Stake in Astria Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Astria Therapeutics Inc - GuruFocus.com
Oppenheimer Forecasts Strong Price Appreciation for Astria Therapeutics (NASDAQ:ATXS) Stock - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Shares Gap Up Following Analyst Upgrade - MarketBeat
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth - Simply Wall St
Astria's HAE Drug Shows 96% Attack Reduction; Phase 3 Set for Q1 2025 | ATXS Stock News - StockTitan
Astria Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - sharewise
FMR LLC Acquires Significant Stake in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Astria Therapeutics Inc - GuruFocus.com
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - XM
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Buy" from Analysts - MarketBeat
Objective long/short (ATXS) Report - Stock Traders Daily
Astria Therapeutics (NASDAQ:ATXS) Shares Up 6.8%Here's What Happened - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema - BioSpace
Astria Therapeutics gains orphan drug status in EU for HAE treatment - Investing.com Australia
(ATXS) Trading Report - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Down 9.2% in September - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%Should You Sell? - MarketBeat
Renaissance Technologies LLC Decreases Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Dimensional Fund Advisors LP Buys 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Cubist Systematic Strategies LLC Purchases New Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Trading 5.2% HigherHere's What Happened - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Millennium Management LLC - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Rating of "Buy" by Analysts - MarketBeat
Insider Sale Alert: Astria Therapeutics Inc [ATXS] – Is it Time to sell? - Knox Daily
Nantahala Capital Management LLC Makes New $6.14 Million Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Are Astria Therapeutics Inc (ATXS) shares a good deal now? - US Post News
Closing Figures Unveiled: Astria Therapeutics Inc (ATXS) Drop -1.17, Closes at 11.01 - The Dwinnex
Logos Global Management LP Decreases Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
ATXSAstria Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - StockTitan
Cubist Systematic Strategies LLC Invests $2.56 Million in Astria Therapeutics, Inc. (NASDAQ:ATXS) - MarketBeat
Driehaus Capital Management LLC Sells 15,057 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics (NASDAQ:ATXS) Earns Buy Rating from HC Wainwright - MarketBeat
Astria Therapeutics to Present at Upcoming Global Angioedema Forum - StockTitan
Financial Snapshot: Analyzing Astria Therapeutics Inc (ATXS)’s Key Ratio Metrics - The Dwinnex
ATXS’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
3.66%
1.11%
자본화:
|
볼륨(24시간):